ResearcherNankai UniversityNo recent work listed
Youguang Luo
Matched on OpenAlex author ID A5110464947. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper
Papers 3
- EB1 phosphorylation mediates the functions of ASK1 in pancreatic cancer development. First author DOI 10.18632/oncotarget.21004↗
- Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer. Co-author DOI 10.18632/oncotarget.12090↗
- Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Co-author DOI 10.1038/aps.2011.130↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jun Zhou · 3 shared papers, 2011–2017 · strength 0.16
- Paper EB1 phosphorylation mediates the functions of ASK1 in pancreatic cancer development. DOI 10.18632/oncotarget.21004↗
- Paper Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer. DOI 10.18632/oncotarget.12090↗
- Paper Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of m… DOI 10.1038/aps.2011.130↗
- Min Liu · 3 shared papers, 2011–2017 · strength 0.16
- Paper EB1 phosphorylation mediates the functions of ASK1 in pancreatic cancer development. DOI 10.18632/oncotarget.21004↗
- Paper Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer. DOI 10.18632/oncotarget.12090↗
- Paper Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of m… DOI 10.1038/aps.2011.130↗
- Dengwen Li · 2 shared papers, 2016–2017 · strength 0.13
- Siqi Gao · 2 shared papers, 2016–2017 · strength 0.13
- Songbo Xie · 1 shared paper, 2016 · strength 0.06
- Xiaodong Sun · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.